Alcohol, Drug Abuse or Dependence w MCC DRG Reimbursement

DRG 896 addresses inpatient stays for alcohol, drug abuse, or dependence without rehabilitation therapy when a Major Complication or Comorbidity is present. This Diagnosis-Related Group is clinically focused on substance-related disorders with significant comorbidity and matters for inpatient reimbursement because the increased severity affects Medicare payment classification.

DRG 896 Overview

DRG 896 covers hospital admissions for alcohol, drug abuse, or dependence where rehabilitation therapy is not provided and a Major Complication or Comorbidity is present. This Diagnosis-Related Group includes cases with significant medical or psychiatric comorbid conditions that increase resource use during inpatient stays. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates the relative weight and reimbursement compared with similar cases without such severity. Accurate clinical documentation of the primary substance-related diagnosis and the Major Complication or Comorbidity is essential for assignment to this Diagnosis-Related Group.

Across payers, negotiated rates for DRG 896 range from a low near $370 up to $45K, with payer medians spanning roughly $2.1K (BCBS) to $27K (Aetna). The widest spread is seen between BCBS’s lower median and Aetna’s much higher median, indicating significant payer variation; see the table and chart below for payer-specific percentiles and distributions. These differences highlight variation across commercial payers including Blue Cross Blue Shield, Anthem, Cigna, and Aetna.

Alaska Benchmarks

Payer means for DRG 896 in Alaska span from $12K (Blue Cross Blue Shield) up to $31K (Cigna), indicating a wide rate range across payers. Cigna’s mean notably exceeds common national central tendencies, producing the largest deviation from national averages. The table and chart below provide the detailed payer distribution and percentiles.

Key Insights for Alaska

Highest-paying payer: Cigna (mean $31K); Lowest-paying payer: BCBS (mean $12K).
Alaska’s payer means range from $12K to $31K, a notably higher ceiling than typical national medians where many payers report means below $20K.
Anthem’s mean ($17K) sits near the state median, while Cigna’s mean substantially exceeds both state and national central tendencies.

Acute inpatient medically supervised withdrawal (detoxification) trials: studies testing protocols for managing severe withdrawal symptoms in hospitalized patients with alcohol or drug dependence who present with life-threatening or complicated withdrawal (presence of comorbid medical illness, high-risk physiology, or co-occurring substance-related medical complications). These trials compare different medication regimens, symptom-monitoring strategies, or care pathways to reduce complications, length of stay, and need for ICU-level care; they focus on the acute stabilization window that defines much of the resource use in this DRG. Results matter to providers and payers because optimizing acute management can decrease morbidity, shorten hospital stays, and reduce high-cost downstream utilization.
Comparative effectiveness studies of integrated inpatient medical-psychiatric management versus standard medical care: pragmatic trials enrolling patients with alcohol or drug dependence complicated by major comorbidities (severe liver disease, infections, overdose-related injury, or severe psychiatric comorbidity) to evaluate coordinated models that combine addiction medicine consultation, psychiatric stabilization, and medical treatment during the same admission. These studies examine outcomes such as hospital readmission, 30-day mortality, initiation of evidence-based addiction treatments prior to discharge, and total episode-of-care costs; they address whether early integration changes short-term clinical trajectories and reduces costly recurrent admissions. For providers and payers, evidence in this area guides investment in multidisciplinary teams and billing/resource allocation for high-acuity patients captured by this DRG.
Post-discharge linkage and outcomes studies focused on transitions of care and relapse prevention: longitudinal cohort studies or randomized implementation trials that enroll patients discharged after hospitalization for alcohol or drug dependence with major complications, testing interventions to improve linkage to outpatient addiction treatment, medication-assisted therapy initiation, or social supports (housing, case management) in the 30- to 180-day post-discharge period. These trials measure readmissions, overdose events, engagement with outpatient services, and healthcare costs to determine which discharge strategies most effectively reduce recurrent inpatient utilization. Payers and hospital administrators use this evidence to design discharge planning, community partnerships, and value-based care initiatives targeted at patients in this high-risk DRG.

The CMS 2023 data are national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 896. These figures reflect Medicare FFS payment activity at the national level for 2023.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$17K	$75K	$14K	9.2K

Patient Population

This DRG’s population includes both Medicare-age beneficiaries and working-age commercially insured patients, representing a mixed-age cohort. Medicare beneficiaries drive a meaningful portion of inpatient utilization given the program’s coverage of older adults, while private/commercial payers cover many younger, working-age patients. Overall, the mix is neither exclusively Medicare-age nor exclusively working-age but spans both groups.

Alaska Benchmarks

Key Insights for Alaska

Highest-paying payer: Cigna (mean $31K); Lowest-paying payer: BCBS (mean $12K).
Alaska’s payer means range from $12K to $31K, a notably higher ceiling than typical national medians where many payers report means below $20K.
Anthem’s mean ($17K) sits near the state median, while Cigna’s mean substantially exceeds both state and national central tendencies.

Acute inpatient medically supervised withdrawal (detoxification) trials: studies testing protocols for managing severe withdrawal symptoms in hospitalized patients with alcohol or drug dependence who present with life-threatening or complicated withdrawal (presence of comorbid medical illness, high-risk physiology, or co-occurring substance-related medical complications). These trials compare different medication regimens, symptom-monitoring strategies, or care pathways to reduce complications, length of stay, and need for ICU-level care; they focus on the acute stabilization window that defines much of the resource use in this DRG. Results matter to providers and payers because optimizing acute management can decrease morbidity, shorten hospital stays, and reduce high-cost downstream utilization.
Comparative effectiveness studies of integrated inpatient medical-psychiatric management versus standard medical care: pragmatic trials enrolling patients with alcohol or drug dependence complicated by major comorbidities (severe liver disease, infections, overdose-related injury, or severe psychiatric comorbidity) to evaluate coordinated models that combine addiction medicine consultation, psychiatric stabilization, and medical treatment during the same admission. These studies examine outcomes such as hospital readmission, 30-day mortality, initiation of evidence-based addiction treatments prior to discharge, and total episode-of-care costs; they address whether early integration changes short-term clinical trajectories and reduces costly recurrent admissions. For providers and payers, evidence in this area guides investment in multidisciplinary teams and billing/resource allocation for high-acuity patients captured by this DRG.
Post-discharge linkage and outcomes studies focused on transitions of care and relapse prevention: longitudinal cohort studies or randomized implementation trials that enroll patients discharged after hospitalization for alcohol or drug dependence with major complications, testing interventions to improve linkage to outpatient addiction treatment, medication-assisted therapy initiation, or social supports (housing, case management) in the 30- to 180-day post-discharge period. These trials measure readmissions, overdose events, engagement with outpatient services, and healthcare costs to determine which discharge strategies most effectively reduce recurrent inpatient utilization. Payers and hospital administrators use this evidence to design discharge planning, community partnerships, and value-based care initiatives targeted at patients in this high-risk DRG.

OpenPayer

Summary & Overview

Alcohol, Drug Abuse or Dependence without Rehabilitation Therapy with MCC: Inpatient Reimbursement Overview

DRG 896 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes